Barr Pharmaceuticals
From Wikipedia, the free encyclopedia
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (September 2008) |
 |
|
| Type | Delaware Corporation |
|---|---|
| Founded | New York (1970) |
| Headquarters | Montvale, NJ, USA |
| Key people | Bruce Downey, CEO |
| Industry | Pharmaceuticals & Medical Devices |
| Products | Generic and Proprietary Pharmaceuticals |
| Revenue | Over $1 Billion USD fiscal year 2005 |
| Employees | 2000 |
| Website | http://www.barrlabs.com |
Barr Pharmaceuticals, Inc., was global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company headquartered in Pomona, New York, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and Pliva d.d. and its subsidiaries. The Company markets more than 120 generic and 25 proprietary products in the U.S. and more than 550 products globally. Its core therapeutic categories include oncology (cancer drugs), female healthcare including hormone replacement and oral contraceptives, cardiovascular, anti-infective and psychotherapeutics. Bruce Downey is the CEO.
[edit] History
Barr Laboratories, Inc. was founded in 1970 by Edwin A. Cohen. Under Cohen's leadership and guidance, Barr overcame many of the many obstacles, associated with a small company and continued to grow and prosper. Mr. Cohen was an inspiration to many in the field, proving that the "little guy" could make a mark in the already established pharmaceutical industry. His special brand of leadership resulted in loyalty and dedication that brought the best products to the market by employees that actually loved their jobs and took pride in their work. Thru his efforts, Barr Laboratories went public.
Barr Laboratories today is a division of Teva Pharmaceuticals. On July 18 2008 it was announced that, Teva Pharmaceutical Industries Ltd will acquire Barr Pharmaceuticals Inc for $7.46 billion plus the assumption of net debt of approximately $1.5 billion.[1] Teva Pharmaceuticals develops and markets generic pharmaceuticals under various brand names - including the the Barr Laboratories, Inc. label. Teva Pharmaceuticals is the largest generic drug manufacturer in the world.
[edit] References
- ^ Staff (2008-07-21), "Teva Coughs Up $7.46B for Barr Reinforcing Its Number One Spot in the Generics Market", Genetic Engineering & Biotechnology News, GEN News Highlights (Mary Ann Liebert), ISSN 1937-8661, http://www.genengnews.com/news/bnitem.aspx?name=38938670, retrieved on 2008-09-26
